Rodman & Renshaw Starts Ritter Pharmaceuticals (RTTR) at Buy, PT $7
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St futures retreat as oil gains on Mideast uncertainty, eyes on Trump-Xi talks
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Qualcomm secures long-term Apple patent deal, easing revenue fears
- Plug Power COO resigns to join another company
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Ritter Pharma (RTTR) Says Phase 2a Lactose Intolerance Trial Data Published in PNAS-Plus
January 3, 2017 5:37 PM ESTRitter Pharmaceuticals, Inc. (NASDAQ: RTTR) today announced that clinical microbiome data from its Phase 2a clinical trial of RP-G28 in patients with lactose intolerance were published in the Proceedings of the National Academy of Science ("PNAS-Plus") PNAS 2017; Early Edition, published ahead of print January 3, 2017.(1)
The paper titled, "Impact of short-chain galactooligosaccharides on the gut microbiome of lactose-intolerant individuals," reports findings on the Company's lead therapeutic candidate, RP-G28, a short-chain galactooligosaccharide ("GOS"). The data validates RP-G28's mechanism of action and supports the product as a potential treatment for lactose intolerance. The newly published... More
